AI assistant
Innoviva, Inc. — Director's Dealing 2012
Aug 29, 2012
32090_dirs_2012-08-28_dd5e1ec1-1d63-47eb-aebe-fbca7ebbf419.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: THERAVANCE INC (THRX)
CIK: 0001080014
Period of Report: 2012-08-24
Reporting Person: Aguiar Michael W (Sr VP, Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-08-24 | Common Stock | M | 4121 | $17.91 | Acquired | 157168 | Direct |
| 2012-08-24 | Common Stock | S | 4121 | $28.01 | Disposed | 153047 | Direct |
| 2012-08-27 | Common Stock | S | 17700 | $27.24 | Disposed | 135347 | Direct |
| 2012-08-27 | Common Stock | S | 2861 | $27.86 | Disposed | 132486 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-08-24 | Stock Option (Right to Buy) | $17.91 | M | 4121 | Disposed | 2015-03-06 | Common Stock (4121) | Direct |
Footnotes
F1: Dispositions made pursuant to a plan intended to comply with rule 10b5-1(c).
F2: This transaction was executed in multiple trades at prices ranging from $28.00 to $28.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $26.70 to $27.69. The price reported above reflects the weighted average sale price.
F4: This transaction was executed in multiple trades at prices ranging from $27.71 to $27.98. The price reported above reflects the weighted average sale price.
F5: Immediately exercisable.